The influenza virus-encoded nonstructural protein 1 (NSl protein) accumulates in the nucleus and is not incorporated into virions. This protein was first identified in 1971 (Lazarowitz et al. 1971 ), but its function has not yet been determined. Data with temperature-sensitive virus mutants suggested that the NSl protein might be involved in the synthesis of virion RNA and/or in the switch to a late pattern of viral protein synthesis (Compans 1973; Wolstenholme et al. 1980; Koennecke et al. 1981; Shimizu et al. 1982) . However, recent experiments have indicated that it is unlikely that the NS1 protein is involved in virion RNA synthesis. An in vitro system that synthesizes virion RNA was not affected by the removal of endogenous NSl protein (Shapiro and Krug ^Present address: The Salk Institute, Swiftwater, Pennsylvania 18370 USA. al. 1989b ). In the absence of the Rev protein, the HIV pre-mRNA accumulates in the nucleus. The Rex protein of human T-cell leukemia virus (HTLV) has the same function (Hanly et al. 1989) . It can be postulated that the influenza virus NSl protein, a nuclear protein (Briedis et al. 1981; Greenspan et al. 1988) , serves the same role.
One of the influenza viral mRNAs that undergoes splicing is NSl mRNA, the mRNA that encodes the NSI protein. A portion of this mRNA is spliced to form NS2 mRNA, which encodes another non-structural protein, the NSl protein (Inglis et al. 1979; Lamb and Choppin 1979) . We inserted the NSl gene into a transient transfection vector and determined whether the NSl protein mediated the transport of unspliced NSl mRNA from the nucleus to the cytoplasm. Surprisingly, we found that rather than facilitating the nucleocytoplasmic transport of NSl mRNA, the NSl protein inhibited the transport of spliced NS2 mRNA. Our results indicate that the NSl protein most likely regulates the nuclear export of NS2 mRNA in a sequence-specific manner. These results identify a novel function of the influenza virus NSl protein and demonstrate that post-transcriptional control of gene expression can occur at the level of the nucleocytoplasmic transport of a mature, spliced mRNA. In addition, the NSl protein inhibited the nucleocytoplasmic transport of its own mRNA-NSl mRNA-which contains all of the sequences in NS2 mRNA. The inhibition of NSl mRNA transport was most evident when it was released from the splicing machinery by mutating its 3'-splice site.
Results

The effect of the NSl and NS2 proteins on the nuclear/cytoplasmic distribution of NSl and NS2 mRNAs
Transient transfections were carried out to determine the role of the NSl and NS2 proteins in the nuclear export of the NSI and NS2 mRNAs. The NSl gene was inserted into a vector (pBC12) under the control of the cytomegalovirus (CMV) major immediate early promoter. The NSI gene was either wild type or contained amber mutations in the NS1 and/or NS2 reading frames (Fig. lA) . COS cells were transfected with each of these plasmids, and the transfected cells were fractionated into nuclei and cytoplasm. Cell-equivalent amounts of nuclear and cytoplasmic RNA, namely 0.5 and 5 |xg, respectively, were used for SI analysis (Fig. I ).
In cells transfected with the wild-type NSl gene (NSl), very little (8%) of the unspliced NSl mRNA was found in the cytoplasm (Fig. IC, lanes 1,2) , suggesting that the NSl protein did not facilitate the transport of unspliced NSl mRNA from the nucleus. Eliminating the synthesis of the NSI protein by one (NSIa) or two (NSIdm) amber mutations actually increased the percentage of the NSI mRNA in the cytoplasm by about threefold (lanes 3-6). As will be documented below, this increase can be attributed to the absence of the NSl protein.
The effects of the NSl protein on the nuclear/cytoplasmic distribution of spliced NS2 mRNA were even more surprising. In cells synthesizing the NSl protein (Fig. IC,  lanes 1,2) , very little (10%) of spliced NS2 mRNA was found in the cytoplasm. Elimination of the synthesis of the NSl protein by amber mutations (lanes 3-6) increased the percentage of the NS2 mRNA in the cytoplasm by five-to sixfold. The amber mutation in the NS2 reading frame (NS2a) had essentially no effect on the percentage of the NS2 mRNA in the cytoplasm (lanes 7,8) . With the amber mutations in both the NSI and NS2 reading frames (NSam3), the percentage of the NS2 mRNA in the cytoplasm (lanes 9,10) was increased to approximately the same extent as with amber mutations in the NSl reading frame alone (lanes 3-6) . Surprisingly, these results suggested that the NSI protein inhibited the transport of spliced NS2 mRNA from the nucleus.
If this were the case, amber mutations in the NSI reading frame should result in a stimulation in the synthesis of the NS2 protein. To test this possibility, COS cells at 72 hr after transfection were labeled with [^''S]methioninc for 6 hr, and equal aliquots were immunoprecipitated with antiserum against either the NSl or NS2 protein (Fig. 2) . In cells transfected with the wild-type NSl gene (lanes 2,8), both the NSI and NS2 proteins were synthesized, indicating that the small percentage of the NSl and NS2 mRNAs that was detected in the cytoplasmic fraction (Fig. I) was actually in the cytoplasm and active in protein synthesis. When NSl protein synthesis was eliminated by one or two amber mutations (Fig. 2 , lanes 9,10), the synthesis of the NS2 protein was stimulated five-to sixfold, the same stimulation that was observed in the percentage of NS2 mRNA that was cytoplasmic ( Fig. 1) . This supports the possibility that the NSI protein inhibited the transport of spliced NS2 mRNA.
The results shown in Figures I and 2 were surprising and exactly opposite to what was postulated. Accordingly, we sought confirmation by other experiments. The most straightforward interpretation of the results Figure 1 . The NSl protein shifted spliced NS2 mRNA into the nucleus. (A) Mutations were introduced using oligonucleotidedirected mutagenesis. For NSl protein amber mutants (NSl a and NSl dm), mutations were introduced into the intron region so that the NS2 amino acid sequence was not affected. With the NS2 protein amber mutant (NS2a), the introduced mutation did not alter the amino acid sequence of the NSl protein, because the two proteins are read off different reading frames. The double amber mutant (NSam3) contained the amber mutations introduced into both the NSl and NS2 reading frames. (C) COS cells were transfected for 48 hr with the plasmids encoding the indicated NSl mRNAs. Cells were then fractionated into nuclei and cytoplasm, and the nuclear and cytoplasmic RNAs were analyzed by SI nuclease assays using the probe depicted in B. The preparation of this probe is described in Materials and methods. After SI nuclease digestion, the protected fragments were resolved on a 5% denaturing polyacrylamide gel. The relative amounts of the NSl and NS2 mRNAs were determined by densitometry of the X-ray film of the gel. The percentage of the NSl and NS2 mRNAs that were in the cytoplasm is indicated under the appropriate lanes. was that the NSl protein directly inhibited the nucleocytoplasmic transport of NS2 (and possibly NSl) mRNA. However, two other interpretations were possible. First, the NSl protein might be acting via splicing, for example, by inhibiting the dissociation of spliced NS2 mRNA from spliceosomes, a step that has recently been shown to require the action of an ATP-requiring protein (Company et al. 1990 ). Second, the NSl protein might be differentially stabilizing the NS2 mRNA in the nucleus and/or destabilizing the NS2 mRNA in the cytoplasm. We tested these two other possibilities experimentally.
The effect of the NSl protein on the nuclear/cytoplasmic distribution of NS2 mRNA was independent of splicing If the NSl protein directly inhibited the transport of NS2 mRNA, then the NSl protein-mediated nuclear retention of NSl mRNA should not be dependent on NS2 mRNA being generated by splicing. For these experiments, NS2 mRNA was expressed without splicing by transfecting the cells with a plasmid containing NS2 cDNA. The NSl protein was provided in trans by a second plasmid encoding an NSl mRNA in which the 3'-splice site AG was mutated to CG and the polypyrimidine tract was disrupted by mutating a T to an A (NS3ss; Fig. 3a ). These mutations did not cause a change in the amino acid sequence of the NSl protein. As shown previously (Alonso-Caplen and Krug 1991), this mutated NSl mRNA was not spliced to form NS2 mRNA, and at least some of this NSl mRNA was exported from the nucleus and translated (also see below). The control plasmid [NS3ss{dm)l not only contained these 3'-splice site mutations but also two amber mutations in the NSl protein reading frame, so that although NSl mRNA was made, no NSl protein was synthesized. Transfections were carried out in 293 cells. Because the plasmids do not replicate in these cells, it was possible to control the relative amounts of the putative target (NS2 mRNA) and effector molecules (NSl protein). When the control plasmid and the NS2 cDNA plasmid (at a 2 : 1 ratio) were cotransfected into 293 cells, the majority (72%) of the NS2 mRNA was in the cytoplasm (Fig. 3b, lanes 1,2) . In contrast, when the NS3ss and NS2 cDNA plasmids (at the same 2 : 1 ratio) were cotransfected into 293 cells, only 10% of the NS2 mRNA was in the cytoplasm (lanes 3,4). The shift in the nuclear/cytoplasmic ratio of the NS2 mRNA caused by the NSl protein was ~23-fold. These results suggested that the NSl protein inhibited the transport of NS2 mRNA whether or not it was generated by splicing. Figure 3 . The NSl protein-mediated shift of NS2 mRNA into the nucleus was independent of splicing, [a] As a source of the NSl protein supplied in trans, the NS3ss construct was used. In this construct, mutations were introduced that disrupted the polypyrimidine tract and altered the 3'-splice site AG -^ CG, without affecting the NSl reading frame. As a control, the NS3ss(dm) mutant was constructed, which not only contained the 3'-splice site mutations but also two amber mutations in the NSl protein reading frame. (t>) 293 cells were cotransfected with either the NS3ss(dm) (-NSl protein) and the NS2 cDNA plasmids at a ratio of 2 : 1 (lanes 1,2) or the NS3ss (-l-NSl protein) and the NS2 cDNA plasmids at a ratio of 2 : 1 (lanes 3,4). All cells were also transfected with the plasmid containing the p-globin minigene. At 40 hr post-transfection, the cells were fractionated into nuclei and cytoplasm. The nuclear and cytoplasmic RNA was extracted and subjected to SI analysis, using the NS-specific probe and p-globin probe depicted in c (see Materials and methods). The NS-specific probe detected both the NS2 and NSl mRNAs. The percentage of the NSl and NS2 mRNAs and unspliced p-globin (uGL) mRNA that were in the cytoplasm is indicated under the appropriate lanes. It should be noted that the unspliced p-globin (uGL) mRNA was predominantly in the nucleus both in the absence and presence of the NSl protein. Spliced P-globin mRNA was predominantly in the cytoplasm (not shown here). As shown previously (Alonso-Caplen and Krug 1991), mutation of the 3'-splice site of unspliced NSl mRNA diverts this mRNA from spliceosomes. The transport of this mutated NSl mRNA, like that of spliced NS2 mRNA, was regulated by the NSl protein. Only a small percentage (8%) of the NSl mRNA encoded by the NS3ss plasmid was found in the cytoplasm (Fig. 3b , lanes 1,2), whereas the majority (78%) of the NSl mRNA encoded by the NS3ss(dm) plasmid was in the cytoplasm (Fig. 3b, lanes 3,4) . The shift in the nuclear/cytoplasmic ratio of the NSl mRNA caused by the NSl protein was ~40-fold. Hence, mutation of its 3'-splice site rendered NSl mRNA more susceptible to regulation by the NSl protein, as the effect of the NSl protein on the nuclear/ cytoplasmic distribution of wild-type spliceable NSl mRNA was much smaller (see Discussion; Fig. 1 ).
The NSl protein did not differentially affect the stability of NS2 mRNAs in the nucleus as compared with the cytoplasm
To exclude the possibility that the NSl protein either stabilized the NS2 mRNA in the nucleus or destabilized the NS2 mRNA in the cytoplasm, we carried out an actinomycin D chase experiment. 293 cells were cotransfected (at a 2 : 1 ratio) either with the NS3ss(dm) (-NSl protein) and NS2 cDNA plasmids or with the NS3ss ( + NS 1 protein) and NS2 cDNA plasmids. At 40 hr after transfection, actinomycin D (5 mg/ml) was added. The amount of NS2 mRNA in the nucleus and cytoplasm was determined at the time of actinomycin D addition and 1 and 4 hr later (Fig. 4) . Both in the absence and the presence of the NSl protein, cytoplasmic NS2 mRNA was less stable than nuclear NS2 mRNA during the course of the actinomycin D treatment. The stability of the NS2 mRNA was slightly higher in the presence of the NSl protein, but the magnitude of this effect was the same in the nucleus and cytoplasm. Thus, the NSl protein did not differentially destabilize the NS2 mRNA in the cytoplasm or differentially stabilize the NS2 mRNA in the nucleus. Similar results were obtained with NSl mRNA containing the 3'-splice site mutation, and the same results were also obtained in COS cell transfections (data not shown). Consequently, it can be concluded that the NSl protein was regulating the nucleocytoplasmic transport of NS2 and NSl mRNAs.
The NSl protein-mediated inhibition of transport is sequence-specific
We determined whether the NSl protein affected the nucleocytoplasmic transport of other influenza viral mRNAs. First, we examined the effect of the NSl protein on the transport of the other influenza virus-spliced mRNA-M2 mRNA encoding an integral membrane protein. This mRNA is generated from Ml mRNA (encoding the membrane protein) utilizing one of two alternative 5'-splice sites (Inglis and Brown 1981; Lamb et al. 1981) . When the other 5'-splice site is utilized, another mRNA, mRNAg, which has only a 9-amino-acid open reading frame, is generated. The mRNAg 5'-splice site Figure 4. The NSl protein did not differentially affect the stability of NS2 mRNA in the nucleus as compared to the cytoplasm. 293 cells were cotransfected with either the NS3ss(dm) (-NSl protein) and NS2 cDNA plasmids at a 2 : 1 ratio or the NS3ss (-I-NSl protein) and NS2 cDNA plasmids at a 2 : 1 ratio. At 40 hr post-translection, cells were either harvested without actinomycin D treatment (0 hr) or treated for 1 or 4 hr with 5 |xg/ml of actinomycin D. Cells were then fractionated into nuclei and cytoplasm. The nuclear and cytoplasmic RNAs were extracted and subjected to SI analysis, using the probes shown in Fig. lb . Equal amounts of RNA (5 jxg of cytoplasmic RNA and 0.5 |xg of nuclear RNA) were used from the different cell samples, (b) The amount of NS2 mRNA in the nucleus and cytoplasm of each sample was determined by densitometry. The relative percentages of NS2 mRNA in the nucleus and cytoplasm at the indicated time points after actinomycin D treatment are presented in the table below, considering the 0 hr value as 100%.
fits the consensus sequence much better than the M2 mRNA 5'-splice site (Fig. 5a ) and, as documented previously (Lamb and Lai 1982) , only the mRNAg 5'-splice site was utilized when plasmids containing the Ml sequence were transfected into cells (data not shown). By mutating the mRNAg 5'-splice site in the Ml sequence from GT to CT, M2 mRNA was synthesized in COS (Fig. 5b) . The identity of the RNA band labeled M2 mRNA was verified by sequence analysis of the region around the splice junction, and both the Ml and M2 proteins were synthesized (data not shown). In both the absence of the NSl protein [cotransfection with NS3ss(dm) plasmid] and the presence of the NSl protein (cotransfection with NS3ss plasmid), the majority (80%) of M2 mRNA was in the cytoplasm. This indicates that the NSl protein had no effect on the transport of spliced M2 mRNA. Similarly, the transport of spliced mRNAg was not affected (data not shown). It should also be noted that unspliced Ml mRNA was largely (85-90%) retained in the nucleus both in the absence and presence of the NSl protein.
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The effect of the NSl protein on the nuclear export of other viral mRNAs was also examined. COS cells were transfected with either the FBI (polymerase basic protein 1), NP (nucleocapsid protein), or HA (hemagglutinin) gene in the presence of NSl protein (supplied in trans by NS3ss plasmid) or its absence [cotransfection with control NS3ss(dm) plasmid]. As shown in Figure 5c , the NSl protein clearly did not affect the nucleocytoplasmic transport of PBl, NP, or HA mRNA. These results obtained from cell fractionation studies were corroborated by translation assays (data not shown).
To verify that the NSl protein recognized sequences in NS2 mRNA, we constructed a PB1-NS2 chimera and determined whether the transport of this chimeric mRNA was inhibited by the NSl protein. In this chimeric mRNA, the NS2 mRNA sequence (418 nucleotides) was flanked at its 5' and 3' ends by 2021 and 320 nucleotides of PBI sequences, respectively (Fig. 6b) . Transfections were carried out in 293 cells (Fig. 6a) . In these cells, PBl mRNA was predominantly (72%) in the cytoplasm, even in the presence of the NSl protein. The PB1-NS2 chimeric mRNA was also predominantly in the cytoplasm (78%) but only in the absence of the NSl protein. As increasing amounts of the NSl protein were provided by a cotransfected NS3ss plasmid, the PB1-NS2 chimeric mRNA was shifted to the nucleus. When the ratio of the NS3ss/PBl-NS2 chimera plasmids was 1.5, the target PBI-NS2 chimeric mRNA was distributed equally between the nucleus and cytoplasm. With a further increase in the ratio of the two plasmids to 3.0, only a minority (13%) of the target PB1-NS2 chimeric mRNA was in the cytoplasm. The shift in the nuclear/cytoplasmic ratio of the chimeric RNA caused by the NSl protein was ~24-fold. Thus, the NSl protein-mediated inhibition of transport requires sequences in NS2 mRNA.
Discussion
We set out to determine whether the influenza virus NSl protein functioned like the HIV Rev protein, namely that the NSl protein facilitated the nucleocytoplasmic transport of an unspliced pre-mRNA-NSl mRNA. Instead, to our surprise, we discovered that the NSl protein regulated the nucleocytoplasmic transport of mRNA in a way that was opposite to that of the wildtype Rev and HTLV Rex proteins. The influenza virus NSl protein inhibited the nuclear export of specific mRNAs. It inhibited the transport of a spliced mRNA-the viral NS2 mRNA-and also the transport of unspliced NSl mRNA-the precursor to NS2 mRNA. The inhibition of NSl mRNA transport was most evident when it was released from its association with the splicing machinery by mutating its 3'-splice site. The shift in the nuclear/cytoplasmic ratio of NS2 and NSl mRNA caused by the NSl protein was large-20-to 40-fold in most experiments. Consequently, the NSl protein may be comparable to the trans-dominant mutants of the Rev and Rex proteins, which apparently inhibit, rather than facilitate, nuclear export of their target mRNAs (Malim et al. 1989a; Bohnlein et al. 1991) .
Like the Rev and Rex proteins, the influenza virus NSl protein appears to regulate the nucleocytoplasmic transport of mRNA in a sequence-specific manner. Of the seven influenza viral mRNAs that were tested, only the transport of the NSl and NS2 mRNAs, which share common sequences, was inhibited by the NSl protein. In its RNA target, the Rev and Rex proteins each recognize an RNA sequence (responsive region, or RE) that forms a highly stable stem-loop structure (Heaphy et al. 1990; Kim et al. 1991) , and the Rev protein has been shown to bind to its cognate RNA sequence (Daly et al. 1989; Zapp and Green 1989) . Our results indicate that the NSl protein-mediated inhibition of transport most likely requires sequences that are common to the NSl and NS2 mRNAs. By analogy with the Rev protein, it is reasonable to expect that the NSl protein will bind to its cognate RNA sequence. The NSl protein has been shown to bind to RNA (Yoshida et al. 1981; Skorko et al. 1991) . Although these earlier studies did not report specificity in the binding of the NSl protein, we have found that the NSl protein specifically binds to NS2 mRNA and have begun to define the specific binding site (Y. Qiu, M.E. Nemeroff, and R.M. Krug, unpubl.). Once this specific binding site is defined, it should be possible to determine whether the NSl protein will bind to, and inhibit the nucleocytoplasmic transport of, other mRNAs in addition to the viral NSl and NS2 mRNAs.
Our evidence indicates that the NSl protein acted directly on the nucleocytoplasmic transport of NS2 mRNA. The NS1 protein caused the nuclear retention of NS2 mRNA whether or not it was generated by splicing, indicating that the NSl protein was not acting by affecting the splicing machinery. In addition, we carried out actinomycin D chase experiments to determine whether the NSl protein differentially affected the stability of NS2 mRNA in the nucleus as compared with the cytoplasm. No such effect was found, indicating that the observed NSl protein-mediated change in the nuclear/cytoplasmic ratio of the NS2 mRNA was the result of a block in the transport of NS2 mRNA caused by the NSl protein.
The control of eukaryotic gene expression has been shown to occur at many levels: transcription, splicing, polyadenylation, and even nucleocytoplasmic transport of unspliced pre-mRNAs (Rev and Rex function). Here, we show that the control of gene expression can also occur at the level of the nucleocytoplasmic transport of a mature, spliced mRNA. A specific protein, the NSl protein, regulates the nucleocytoplasmic transport of a specific mature, spliced mRNA-the NSl mRNA-and.
hence, regulates the amount of synthesis of the protein encoded by this mRNA. It will be important to determine whether this type of post-transcriptional regulation occurs in other systems. Regulated nucleat export of RNA We predict that the NSl protein via binding to its cognate sequence in NS2 mRNA will inhibit the transport of NSl mRNA not only in transfected cells but also in influenza virus-infected cells. As a consequence, the amount of the NS2 protein in influenza virus-infected cells would be controlled at several levels (Fig. 7) . First, the amount of NS2 mRNA that is generated by splicing would be suppressed. This would be accomplished both by the suppression of the rate of splicing of NSl mRNA via cis-acting sequences in NSl mRNA itself (Plotch and Krug 1986; Agris et al. 1989; Nemeroff et al. 1992) and by the enhanced nuclear export of unspliced NSl mRNA. In addition, the NSl protein encoded by unspliced NSl mRNA would down-regulate the nucleocytoplasmic transport of NS2 mRNA. This down-regulation may be necessary because, as discussed below, the transport of all viral mRNAs may be rapid in influenza virus-infected cells. Consequently, the genetic information in the influenza virus NS gene would be directed toward the regulated production of a low amount of the NS2 protein, one of the two proteins encoded in this gene. This regulation is entirely post-transcriptional, at the level of splicing and nuclear export of mRNA. There may be very little, if any, transcriptional control during influenza virus infection. At early times of infection, the NSl and NP proteins are selectively synthesized (Hay et al. 1977; Smith and Hay 1982; Shapiro et al. 1987) , but this is the result of the selective synthesis of specific genomic RNAs rather than the regulation of the amount of synthesis of mRNAs transcribed from these genomic RNAs. It is tempting to speculate that post-transcriptional controls of influenza viral gene expression evolved because, unlike DNA genomes, this viral RNA genome lacks upstream promoter-enhancer sequences that can be regulated by trans-acting factors. There is a common sequence of 12 nucleotides at the 3'-terminus of each of the eight genomic RNAs of influenza A virus (Skehel and Hay 1978; Desselberger et al. 1980; Robertson 1981) , and as a consequence, selective and regulated transcription of a given genomic RNA segment may not be possible.
Why would it be necessary for influenza virus to regulate the synthesis of the NS2 protein so closely? This is difficult to answer because the function of the NS2 protein is not known. A recent paper reported the intriguing result that mutations in the NS2 reading frame were associated with the generation of defective-interfering RNAs derived from at least one of the three viral polymerase genes (Odagiri and Tobita 1990) . This might mean that the NS2 protein is involved in some aspect of viral RNA replication and that changes in the NS2 protein can lead to aberrant RNA synthesis. Perhaps the level of the NS2 protein must be closely controlled so that there is enough for efficient viral RNA replication but not an excess that could lead to aberrant RNA synthesis and the production of defective-interfering RNAs.
Does the NSl protein also down-regulate the transport of its own mRNA in influenza virus-infected cells? In transfected cells, wild-type NS 1 mRNA was inefficiently transported from the nucleus. Even though there was some increase in transport when the synthesis of the NSl protein was eliminated, the majority of the NSl mRNA remained in the nucleus, presumably because it was associated with spliceosomes. In contrast, NSl mRNA containing a mutated 3'-splice site was efficiently transported in the absence of the NSl protein, presumably because it was not associated with spliceosomes, and the transport of this mutated NSl mRNA was effectively inhibited by the NSl protein. A key question, then, is whether most of the nuclear NSl mRNA in influenza virus-infected cells is on spliceosomes. If, as discussed below, most of the nuclear NSl mRNA in infected cells is in the process of being rapidly transported rather than being associated with spliceosomes, then the transport of these NSl mRNA molecules would be expected to be regulated by the NSl protein.
The most definitive way to determine how the NSl protein regulates the transport of the NS2 and NSl mRNAs in influenza virus-infected cells is to introduce into virus a NS gene that encodes a mutated loss-of-function NSl protein. The technology for introducing specific mutations into the influenza virus genome has recently been developed (Luytjes et al. 1989) . It is reasonable to hypothesize that the NSl protein has the same types of functional domains as the Rev protein: one that interacts with the target sequence, or RE, on the mRNA; and one that likely interacts with the nuclear export machinery (Malim et al. 1989a) . Mutations in the latter domain of the Rev protein yield the trans-dominant Rev mutants. We are currently characterizing a series of mutant NS 1 proteins to identify the functional domains in the NSl protein. The appropriate mutant NS genes will then be introduced into virus.
Neither the NSl protein nor the NS2 protein facilitated the nucleocytoplasmic transport of unspliced NS 1 mRNA, and the NSl protein did not facilitate the transFigute 5. The NSl protein did not affect the nuclear export of other influenza viral mRNAs, including the viral spliced mRNA, M2 mRNA, and the FBI, HA, and NP mRNAs.
[a] Transfection with the Ml gene produced only spliced mRNAg and not M2 mRNA. To activate splicing at the M2 5'-splice site, the mRNAj 5' splice site was mutated, from GT to CT (mRNAg 5'ss mutant), (b) Cos cells were transfected with the plasmid containing the mutated mRNAs 5'ss in the presence (cotransfection with NS3ss plasmid) or absence [cotransfection with NS3ss(dm) plasmid] of the NSl protein. At 48 hr post-transfection, cells were fractionated into nuclei and cytoplasm, and the RNA from each fraction was extracted and subjected to SI analysis using the probe for Ml and M2 mRNAs described in the Materials and methods, (c) Cos cells were transfected with the PBl, HA, or NP gene in the absence of NSl protein [cotransfection with NS3ss(dm) plasmid] or presence of NSl protein (cotransfection with NS3ss plasmid). Cells were fractionated into nuclei and cytoplasm, and the RNA from each fraction was assayed by SI nuclease protection analysis using the probes for PBl, HA, or NP mRNA described in Materials and methods.
Cold In the first four lanes, the ratio of NS3ss to PBl plasmid and the ratio of the NS3ss(dm) to PB1-NS2 plasmid was 2 : 1; a ratio of 3 : 1 yielded the same result. Different amounts of the NS3ss plasmid were cotransfected with the plasmid encoding the PB1-NS2 mRNA chimera. The numbers above the last four lanes indicate the ratio of the NS3ss/PBl-NS2 plasmid used for transfection. At 48 hr posttransfection, cells were fractionated into nuclei and the cytoplasm, and extracted RNA was subjected to SI nuclease protection assay using the probe depicted in b. The relative amount of PBl mRNA and of the PB1-NS2 mRNA chimera in the nucleus and cytoplasm of each sample was determined by densitometry. The percentage of these mRNAs that were in the cytoplasm is indicated under the appropriate lanes. port of unspliced Ml mRNA. This suggests that the efficient nucleocytoplasmic transport of unspliced NSl and Ml mRNAs in influenza virus-infected cells may not require the action of a Rev-like virus-specific protein. An alternative possibility is that there is a competition between transport and spliceosome formation for each species of pre-mRNA and that, consequently, a change in the overall rate of transport of all nuclear mRNAs and pre-mRNAs will lead to a change in the efficiency of transport of a given pre-mRNA, like the NSl or Ml mRNA. In adenovirus-infected cells, the transport of virus-specific mRNAs and heterologous mRNAs encoded in an adenovirus vector may be significantly slower than the transport of all mRNAs in uninfected cells (Berkner and Sharp 1984, 1985; Mansour et al. 1985; Alonso-Caplen et al. 1988) , thereby explaining the lack of transport of NSl mRNA that we observed when NSl mRNA was expressed with an adenovirus vector (Alonso-Caplen and Krug 1991). In cells in which NSl mRNA or Ml mRNA was expressed with a transient transfection vector, nucleocytoplasmic transport may be slightly more rapid, as a small amount (-10-20%) of unspliced NSl and Ml mRNAs was exported from the nucleus and translated (this study). Finally, in influenza virus-infected cells the transport of all viral mRNAs may be quite rapid (Herz et al. 1981; Shapiro et al. 1987) , thereby enabling unspliced NSl and Ml mRNAs to be transported efficiently without the intervention of a Rev-like protein. Host mRNAs and their precursors would not be subjected to this rapid transport because they are degraded in the nucleus, presumably as a result of cleavage of their 5' ends by the virus-encoded capdependent endonuclease (Katze and Krug 1984) . Clearly, it will be important to determine what causes the increased rate of transport of all viral mRNAs in influenza virus-infected cells.
In summary, 20 years after its discovery, we have identified at least one function of the NSl protein. Surprisingly, it down-regulates the nuclear export of the viral spliced NS2 mRNA and its unspliced precursor, NSl mRNA.
Materials and methods
Construction of plasmids
Oligonucleotide-directed mutagenesis with a bacteriophage M13 mutagenesis system (Boehringer Mannheim Biochemicals) was used to introduce point mutations into the NSl or Ml gene.
The mutations were confirmed by dideoxynucleotide sequencing. The various mutations are described in Figures 1, 3 , and 5. All wild-type and mutant genes were inserted into the pBC12 transfection vector (obtained from B. Cullen|, which placed the genes under the control of the CMV immediate early promoter. Vector pBC12/CMV/IL-2 was digested with Hindlll and Smal to remove the interleukin (IL-2) gene. The resulting ends of the plasmid were blunt-ended using the Klenow fragment. All wild-type or mutant NSl, Ml, PBl, HA, and NP genes, and the Pglobin minigene (Perkins et al. 1986) , with the exception of the NS3ss(dm) DNA (see Fig. 3 ), were inserted into the vector by blunt-end ligation. For the insertion of the NS3ss(dm) DNA, a BamHl linker was added to the ends of the plasmid (plasmid pBC12B). The NS3ss(dm) DNA, which contains BamHl ends, was inserted by sticky-end ligation into pBC12B. WUd-type NSl, NS2, and Ml cDNAs from influenza virus A/Udorn/72 were obtained from R. Lamb. The PBl, HA, and NP genes from influenza virus A/PR/8/34 were obtained from P. Palese.
Cell culture and transfection
COS cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum and were transfected with 1 M-g/ml of plasmid DNA using DEAE-dextran and chloroquine (Cullen 1987) . 293 cells were also maintained in DME containing 10% fetal calf serum and were transfected with 5-20 ixg/ml of plasmid DNA, as indicated in the figure legends, by the calcium phosphate method (Davis et al. 1986) .
RNA extraction and analysis
Transfected COS cell cultures were harvested from 48 to 72 hr post-transfection, whereas transfected 293 cells were harvested from 36 to 48 hr post-transfection. The cells were fractionated into nuclei and cytoplasm, as described previously (Greenberg and Ziff 1984) . The fractionation was monitored by phase-contrast microscopy of the nuclear fraction and by agarose gel analysis to determine the presence of rRNA markers characteristic of the nucleus {45S) and of the cytoplasm (18S). In addition, in one experiment (Fig. 3) , the fractionation was monitored by cotransfecting with a p-globin minigene and determining the nuclear/cytoplasmic distribution of unspliced and spliced p-globin mRNAs. RNA was extracted using the guanidinium isothiocyanate (Chomcynski and Sacchi 1987) method. The amount of RNA in the cytoplasm and nucleus was determined both by absorbance at 260 nm and by quantitating the ethidium-stained agarose gel analysis of the cytoplasmic and nuclear RNAs. Reproducible recoveries of cytoplasmic and nuclear RNAs were obtained. Cell-equivalent amounts of nuclear (0.5 |xg) and cytoplasmic RNAs (5 |xg) were assayed by SI nuclease protection using 5' end-labeled single-stranded DNA probes (Davis et al. 1986 ). Several different probes were used to assay NSl and NS2 mRNAs. For the experiment described in Figure 1 , the probe for NSl and NS2 mRNAs (see Fig. lb ) was obtained by ligating an JVcoI-£coRI fragment derived from recombinant pBC 12 containing wild-type or mutant NSl DNA to the Smal£coRI large fragment of M13mp9. A 29-mer oligonucleotide complementary to pBC12 sequences was kinased at the 5' end with [7-^^P]ATP and was annealed to single-stranded DNA from the M13mp9 containing the NSl DNA sequences. After primer extension using the Klenow fragment followed by Aval digestion, the probe was purified on an alkaline-denaturing agarose gel. For the experiment described in Figure 3 , the probe for NSl and NS2 mRNAs was obtained by using a 30-mer oligonucleotide complementary to the NS3ss or NS3ss(dm) sequence, 200 nucleotides downstream from the 3'-splice site (see Fig. lb) . After labeling the oligonucleotide at its 5' end with [7-^^P]ATP, it was annealed to single-stranded DNA from M13mp9 containing NS3ss or NS3ss(dm) DNAs. This was followed by primer extension using the Klenow fragment. Aval digestion, and purification. This probe not only protected NSl mRNA from the NS2 cDNA but also NSl mRNA transcribed from the cotransfecting plasmids, NS3ss(dm) and NS3ss.
The SI assay probe used to detect Ml and M2 mRNAs was generated as follows. The mRNA,, 5'ss mutant was subcloned into the pBC12 transfection vector. A Sstl-Accl restriction fragment, containing the pBC12 CMV leader. Ml 5' exon, and some Ml intron sequence was subcloned into Sstl-Accl.
Singlestranded DNA prepared from this recombinant M13 construct was annealed to two synthetic oligonucleotides, one complementary to the Fokl site of pBC12 and one complementary to the Aval site of M13mpl9. The partially duplexed DNA was then digested with Aval and Fokl. The single-stranded FoklAval restriction fragment generated was end-labeled at the Fokl end by filling in with [a-'^PjdGTP and using the Klenow fragment. To detect PBl mRNA or the PB1-NS2 chimeric mRNA (see Fig. 6b ), a 23-mer oligonucleotide complementary to PBl sequences was kinased at the 5' end with |7-'^^P1ATP and was annealed to M13mp9 containing PBl DNA. After primer extension using the Klenow fragment, the probe was digested with Aval and purified. A similar strategy was used to make probes to detect HA, NP, and globin mRNAs except that the primer oligonucleotides, which were complementary to HA, NP, or globin sequences, were annealed to M13mp9 containing HA, NP, or globin DNA, respectively.
Determination of NSl and NS2 protein levels
At 72 hr post-transfection, COS cells were labeled for 6 hr with 200 fxCi/ml of [^^S]methionine in media depleted of 80% of its methionine. Cells were lysed as described previously (AlonsoCaplen et al. 1988) , and NSl and NS2 proteins were immunoprecipitated using monospecific antibodies obtained from M. Krystal and P. Palese (Young et al. 1983; Greenspan et al. 1985) . Proteins were analyzed on 20% SDS-polyacrylamide gels.
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